Orgenesis Inc.: directors' dealings · United States · SEC (Form 4)

About Orgenesis Inc.

Orgenesis Inc. is a U.S.-based biotechnology company focused on decentralized cell and gene therapy manufacturing and commercialization. The company is headquartered in Germantown, Maryland, United States. Historically, Orgenesis was listed on the NASDAQ under the ticker ORGS; more recently, the stock has traded on the OTC market following its 2025 Nasdaq delisting. From an equity analyst’s perspective, Orgenesis should be viewed as a niche advanced-therapy platform company rather than a traditional drug developer. The company’s core strategy is built around its POCare platform, which is intended to bring cell and gene therapies closer to the point of care. Orgenesis positions this platform as a way to reduce the cost, complexity, and logistical burden associated with personalized therapies. Its model is organized around three main components. POCare Therapies is the therapeutic pipeline and partnering layer, where Orgenesis seeks promising early-stage programs and brings development and validation in-house. POCare Technologies covers customized, automated processing systems designed to support scalable, GMP-compliant production. POCare Network is the collaboration layer, linking Orgenesis with academic institutions, hospitals, and biotech partners to support development, production, and eventual distribution. A key part of the company’s differentiation is its focus on decentralized manufacturing infrastructure, including Orgenesis Mobile Processing Units and Labs (OMPUL). These mobile or modular processing concepts are designed to standardize production environments and shorten implementation timelines, which is important in an industry where centralized manufacturing can be expensive and operationally rigid. In practical terms, Orgenesis is trying to create a harmonized, reproducible framework for advanced therapy manufacturing that can be deployed locally. Orgenesis targets several therapeutic areas, including immuno-oncology, viral diseases, metabolic and autoimmune disorders, vascular and musculoskeletal diseases, and kidney disease. That said, investors should note that the company remains in a high-risk category, with execution dependent on partner adoption, regulatory progress, funding availability, and successful commercialization of platform assets. Recent developments have included continued restructuring around the public listing status after Nasdaq delisting, as well as financing-related disclosures and governance changes in recent SEC materials. For French-speaking investors evaluating U.S.-listed healthcare microcaps, Orgenesis offers a differentiated technology story in Santé & Pharma, but one that carries material dilution, liquidity, and execution risk.